Flt4 - FMS-like tyrosine kinase 4 Gene

中文名称：fms 样酪氨酸激酶4

种属: Mus musculus

同用名: Chy; Flt-4; VEGFR3; VEGFR-3

基因 ID: 14257 | 基因类型: protein coding

关于 Flt4

Chromosome 11: 49,500,090-49,543,566 forward strand.GRCm39:CM001004.3

This gene has 2 transcripts (splice variants), 196 orthologues, 53 paralogues and is associated with 27 phenotypes. Broad expression in lung adult (RPKM 14.6), ovary adult (RPKM 1.5) and 23 other tissues.

功能概要

该基因编码的蛋白可启动血管内皮生长因子激活受体活性。参与淋巴管生成；调节血管重塑；和发芽的血管生成。作用于肺泡发育的上游或内部；细胞群增殖的正向调节；和呼吸系统过程。预测位于胞质溶胶中；核质；和质膜。预计是受体复合体的一部分。预计是质膜的组成部分。以多种结构表达，包括消化系统；鳃弓;心血管系统;中枢神经系统;和胚外成分。用于研究遗传性淋巴水肿。该基因的人类直系同源物与遗传性淋巴水肿 IA 有关。与人类 FLT4（fms 相关受体酪氨酸激酶 4）同源。 [由基因组资源联盟提供，2022 年 4 月]

Enables vascular endothelial growth factor-activated receptor activity. Involved in lymphangiogenesis; regulation of blood vessel remodeling; and sprouting angiogenesis. Acts upstream of or within lung alveolus development; positive regulation of cell population proliferation; and respiratory system process. Predicted to be located in cytosol; nucleoplasm; and plasma membrane. Predicted to be part of receptor complex. Predicted to be integral component of plasma membrane. Is expressed in several structures, including alimentary system; branchial arch; cardiovascular system; central nervous system; and extraembryonic component. Used to study hereditary lymphedema. Human ortholog(s) of this gene implicated in hereditary lymphedema IA. Orthologous to human FLT4 (fms related receptor tyrosine kinase 4). [provided by Alliance of Genome Resources, Apr 2022]

Flt4 基因产物(1)

mRNA	Protein	Name
NM_008029.3	NP_032055.1	vascular endothelial growth factor receptor 3 precursor

Flt4 蛋白结构

IgI_VEGFR

IG_like

VEGFR-2_TMD

PKc_like

0
300
600
900
1200
1363 a.a.

蛋白主名

其他名称

vascular endothelial growth factor receptor 3

chylous ascites	receptor protein tyrosine kinase
tyrosine-protein kinase receptor FLT4

重组 Flt4 蛋白

目录号	产品名	蛋白编号	纯度
HY-P74466	VEGFR-3/FLT4 Protein, Mouse (HEK293, His)	P35917 (Y25-E775)	≥95%
HY-P74467	VEGFR-3/FLT4 Protein, Mouse (HEK293, hFc)	P35917 (Y25-E775)	≥95%

相关产品

Approval

生物活性分子 (3)

目录号	产品名	纯度	是否罕见病
HY-10260	Vandetanib	99.95%	是
HY-10260B	Vandetanib hydrochloride	/	否
HY-10260A	Vandetanib trifluoroacetate	/	否

Clinical Phase

生物活性分子 (7)

目录号	产品名	作用方式	纯度	Phase
HY-10205	Cediranib		99.58%	Phase 3
HY-100019	Rogaratinib	Inhibitor	99.86%	Phase 3
HY-13314	Tesevatinib	Inhibitor	99.21%	Phase 3
HY-13049	Cediranib maleate		99.95%	Phase 3
HY-13034	Gandotinib	Inhibitor	99.82%	Phase 2
HY-10987A	ENMD-2076		99.12%	Phase 2
HY-10987	ENMD-2076 Tartrate		99.42%	Phase 2

Pre-clinical Phase

生物活性分子 (11)

Cat. No.	产品名	作用方式	纯度	是否罕见病
HY-116624	MAZ51		99.96%	否
HY-119933	RIPK1-IN-7	Inhibitor	98.67%	否
HY-145293	TNIK-IN-3	Inhibitor	99.88%	否
HY-15813	FIIN-1	Inhibitor	99.11%	否
HY-10260S	Vandetanib-d6		/	否
HY-10260S1	Vandetanib-d4		/	否
HY-110272	Vatalanib succinate	Inhibitor	/	否
HY-155178	Antiproliferative agent-34	Inhibitor	/	否
HY-RS04994	FLT4 Human Pre-designed siRNA Set A		/	否
HY-RS04995	Flt4 Mouse Pre-designed siRNA Set A		/	否
HY-RS04996	Flt4 Rat Pre-designed siRNA Set A		/	否

直系同源

种属	基因名	来源	基因 ID
Homo sapiens	Flt4	NCBI	NCBI:2324
Rattus norvegicus	Flt4	NCBI	NCBI:114110

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。沪(浦)应急管危经许[2021]201709(QFYS)	站点地图隐私声明
Copyright © 2013-2024 MedChemExpress. All Rights Reserved.	沪ICP备15051369号-4

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。沪(浦)应急管危经许[2021]201709(QFYS)

站点地图隐私声明